FORIMMUN
RESEARCH NETWORK FOR NEW STRATEGIES IN IMMUNOTHERAPY
The association
Within the framework of the 12 forimmun projects, new strategies are being developed together with 11 biotech companies to combat tumors and infections. The aim of the research network forimmun - New Strategies in Immunotherapy" is the development of novel concepts for the treatment of these diseases by means of defined manipulations of the body's defense mechanisms. Future achievements in this area will build upon recent progress made in the fields of genome research and molecular immunology. forimmun is funded by the Bavarian research foundation with 2.5 million Euro for three years. Despite increasing medical progress cancer and infectious diseases continue to be a substantial threat for the human population. Conventional therapies such as antibiotics, chemotherapy, surgery and irradiation have reached their limits. The occurrence of mutations and drug-resistance in pathogens and tumor cells cause considerable problems, as is the case for HIV (AIDS), where so far no vaccine has been developed. But also new variants of viruses and bacteria, like SARS or EHEC, are a great challenge for medical research. These examples point out that alternative therapeutic concepts for prevention and treatment of cancer and infections are required. Our immune system has the potential to recognize and respond to a variety of danger signals. Such signals may originate from attacks by infectious organisms, but may also result from internal harm caused by cancer cells. However, neoplastic cells and pathogens have gained skills to escape recognition and elimination by the immune response. Therefore, the new approach of immune therapy aims at restoring the bodys intrinsic capacity to recognize, attack and eliminate microbes and malignant cells.
Organisation
Scientists
- Arthur Altenhöfer
- Karen Balbach
- Asli Bauer
- Dr. Stefan Bauer
- Dr. Birgit Bergmann
- Niklas Beyersdorf
- Dr. Hildegard Büning
- Dr. Marcela Fajardo-Moser
- Dr. Joachim Fensterle
- PD Dr. Ivaylo Gentschev
- Christine Hambrecht
- Monika Hamelmann
- Dr. Antje Heidt
- Stefan Homburg
- Margarita Jurke
- Dr. Thomas Kerkau
- Dr. Matthias Kieslinger
- Dr. Frank Notka
- Dr. Sabine Pilgrim
- Tamara Potapenko
- Andreas Schmidt
- Barbara Spies
- Jochen Stritzker
- Dr. Marion Thellmann
- Veronika Wanninger
- Dr. Jens Wild
- Dr. Gisela Wohlleben
Head of Research Division
General Management
Second Spokesperson
Spokesperson
Partner
Scientific partner
- LMU München
- Genzentrum
- Max von Pettenkofer Institut
- TU München
- Institut für Medizinische Mikrobiologie, Immunologie und Hygiene am Klinikum rechts der Isar
- Universität Erlangen
- Universität Regensburg
- Universität Würzburg
- Institut für Medizinische Strahlenkunde und Zellforschung
- Institut für Molekulare Infektionsbiologie
- Institut für Virologie und Immunbiologie
- Theodor-Boveri-Institut am Biozentrum - Lehrstuhl für Mikrobiologie
Partner of the industry
- AKZO NOBEL Intervet International bv
- TeGenero AG
- sirenade AG
- responsif GmbH
- november AG
- Merix Germany GmbH
- MediGene
- GENEART GmbH
- Corixa Corporation
- Coley Pharmaceuticals GmbH
- Ardeypharm GmbH
- TheraImmune GmbH
Projects
- Tumor Vaccine
- Immunotherapy of infections
- Immune Modulation
News
Publications
-
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917.
Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Dobrindt U. (2004) J Bacteriol 186: 5432-5441
-
Atopic disorders: a vaccine around the corner?
Wohlleben G, Erb KJ. (2001) Trends Immunol 22: 618-626. Review
Datei-Download
-
Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.
Waidmann M, Bechtold O, Frick JS, Lehr HA, Schubert S, Dobrindt U, Loeffler J, Bohn E, Autenrieth IB. (2003) Gastroenterology 125: 162-177
-
Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery.
Pilgrim S, Stritzker J, Schoen C, Kolb-Maurer A, Geginat G, Loessner MJ, Gentschev I, Goebel W. (2003) Gene Ther 10(24): 2036-2045
Datei-Download
-
Cloning of herpesviral genomes as bacterial artificial chromosomes.
Adler H, Messerle M, Koszinowski UH. (2003) Rev Med Virol 13: 111-121. Review
Datei-Download
-
CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
Maurer T, Heit A, Hochrein H, Ampenberger F, O Keeffe M, Bauer S, Lipford GB, Vabulas RM, Wagner H. (2002) Eur J Immunol 32:2356-64.
Datei-Download
-
Delivery of protein antigens and DNA by attenuated intracellular bacteria.
Gentschev I, Dietrich G, Spreng S, Pilgrim S, Stritzker J, Kolb-Maurer A, Goebel W. (2002) Int J Med Microbiol 291: 577-582
-
Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be mediated by molecularly defined antigens.
BERBERICH, C., J. R. RAMIREZ-PINEDA, C. HAMBRECHT, G. ALBER, Y. A. W. SKEIKY and H. MOLL (2003). J. Immunol. 170: 3171-3179.
Datei-Download
-
Dendritic cell-based vaccination against tumors and infectious diseases.
BERBERICH, C., W. STRITTMATTER and H. MOLL (2002). In: Vaccine Delivery Strategies, G. Dietrich and W. Goebel (eds.), Horizon Scientific Press, Wymondham, U.K., pp. 349-368.
-
Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis.
MOLL, H. and C. BERBERICH (2001). Immunobiol. 204: 659-666. Review
-
Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H. (2004) J Immunol 172(10): 6281-6289
Datei-Download
-
Dendritic cells and host resistance to infections.
MOLL, H. (2003). Cell. Microbiol. 5: 493-500. Review.
Datei-Download
-
Dendritic cells as a tool to combat infectious diseases.
MOLL, H. (2003). Immunol. Letters 85: 153-157. Review.
Datei-Download
-
Dendritic cells as vectors for vaccination against infectious diseases.
MOLL, H. and C. BERBERICH (2001). Int. J. Med. Microbiol. 291: 323-329. Review.
-
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Lin CH, Hunig T. (2003) Eur J Immunol 33: 626-638
Datei-Download
-
Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways.
Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, Suter M, Wagner H. (2004) PNAS 101 (31): 11416-11421
Datei-Download
-
Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines.
Bojak A, Wild J, Deml L, Wagner R. (2002) Intervirology 45: 275-286
Datei-Download
-
Increased interleukin (IL) 4 receptor expression and IL-4-induced decrease of IL-12 production by Langerhans cells infected with Leishmania major.
MOLL, H., A. SCHARNER and E. KÄMPGEN (2002). Infect. Immun. 70: 1627-1630.
Datei-Download
-
Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J, Bojak A, Deml L, Wagner R. (2004) Vaccine 22: 1732-1743
Datei-Download
-
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, Wolf H, Wagner R. (2001) J Virol 75(22): 10991-11001
Datei-Download
-
Novel vaccines protecting against the development of allergic disorders: a double-edged sword?
Erb KJ, Wohlleben G. (2002) Curr Opin Immunol 14: 633-643. Review
Datei-Download
-
Prokaryotic chromosomes and disease.
Hacker J, Hentschel U, Dobrindt U. (2003) Science 301: 790-793
Datei-Download
-
Raf kinases in lung tumor development.
Rapp UR, Fensterle J, Albert S, Gotz R. (2003) Adv Enzyme Regul 43: 183-195. Review
-
Recombinant murine polyoma virus-like-particles induce protective anti-tumor immunity.
Brinkman M, Walter J, Jennes I, Neugebauer M, Bertling W, Grein S, Thies M, Weigand M, Beyer T, Herrmann M, Reiser C, Hess J. (2004) Lett Drug Des Dics 1: 137-147
-
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.
Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R. J Exp Med. 2005 Aug 1;202(3):445-55.
Datei-Download
-
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. (2004) Science 303: 1526-1529
Datei-Download
-
The E. coli alpha-hemolysin secretion system and its use in vaccine development.
Gentschev I, Dietrich G, Goebel W. Trends Microbiol 10: 39-45. Review
Datei-Download
-
The influence of infections on the development and severity of allergic disorders.
Herz U, Lacy P, Renz H, Erb K. (2000) Curr Opin Immunol 12: 632-640. Review
Datei-Download
-
The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4.
Brattig NW, Bazzocchi C, Kirschning CJ, Reiling N, Buttner DW, Ceciliani F, Geisinger F, Hochrein H, Ernst M, Wagner H, Bandi C, Hoerauf A. (2004) J Immunol 173: 437-445
Datei-Download
-
The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens.
Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, Oelschlaeger TA. (2004) FEMS Immunol Med Microbiol 40(3): 223-229
-
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.
Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hunig T. (2003) J Exp Med 197: 955-966
-
Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice.
Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, Heit A, Wagner H. (2003) J Immunol 171(11): 5908-5912
Events
-
03.10.2005
Symposium - Advances in Immunotherapy
-
05.11.2004
Analytica 2004
-
22.10.2004
4. Münchner Wissenschaftstage im Jahr der Technik 2004
-
14.06.2004
3. Mitgliederversammlung am 14.Juni 2004 mit Vorträgen zum Thema: Genomforschung und Immuntherapie: Neue Chancen für therapeutische Entwicklungen
-
29.02.2004
STRATEGIES FOR IMMUNE THERAPY
-
18.07.2003
Mit Genen heilen: Chance oder Risiko
-
04.06.2003
2. Mitgliederversammlung forimmun; Vorträge zum Thema:Prionenerkrankungen, Krebs, Infektionen: Die molekulare Medizin vor neuen Herausforderungen
Contact
Dr. Nadja Huttner
LMU München
Max von Pettenkofer Institut
Pettenkofer-Str. 9a
80336 München
Telefon: +49-89-5160 5433
Email: <link>info@forimmun.de